District Of Columbia 2023 2023-2024 Regular Session

District Of Columbia Council Bill B25-0034 Enrolled / Bill

Filed 06/20/2023

                      	ENROLLED ORIGINAL 
 
 
 
 
 	1 
AN ACT 
 
______________ 
 
IN THE COUNCIL OF THE DISTRICT OF COLUMBIA 
 
___________________ 
 
 
To amend the Women’s Health and Cancer Rights Federal Law Conformity Act of 2000 to 
require an individual or group health benefit plan to provide coverage for the diagnosis 
and treatment of infertility and standard fertility preservation services, and to require a 
health insurer offering health insurance coverage through Medicaid and the DC 
Healthcare Alliance program to cover the diagnosis and medication treatment of 
infertility. 
 
BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this 
act may be cited as the “Expanding Access to Fertility Treatment Amendment Act of 2023”. 
 
Sec. 2. The Women’s Health and Cancer Rights Federal Law Conformity Act of 2000, 
effective April 3, 2001 (D.C. Law 13-254; D.C. Official Code § 31-3831 et seq.), is amended as 
follows:  
(a) Section 5d (D.C. Official Code § 31-3834.04) is amended as follows: 
  (1) Subsection (a)(1) is amended by striking the phrase “drugs, devices, products, 
and services under sections 5a, 5b, and 5c.” and inserting the phrase “or fertility enhancing 
drugs, devices, products, and services under sections 5a, 5b, 5c, and 5f.” in its place. 
 (2) Subsection (c) is amended as follows:  
(A) The lead-in language is amended by striking the phrase “, or 5c” and 
inserting the phrase “, 5c, or 5f” in its place.  
(B) Paragraph (1) is amended by striking the phrase “contraceptive drugs” 
and inserting the phrase “contraceptive or fertility enhancing drugs” in its place.  
(C) Paragraph (2) is amended by striking the phrase “contraceptive drugs” 
and inserting the phrase “contraceptive or fertility enhancing drugs” in its place. 
(3) Subsection (d) is amended as follows: 
 (A) Paragraph (1) is amended by striking the phrase “contraceptive drugs” 
and inserting the phrase “contraceptive or fertility enhancing drugs” in its place. 
 (B) Paragraph (2) is amended by striking the phrase “drugs, devices, 
products, or services required to be covered under sections 5a, 5b, or 5c.”  and inserting the 
phrase “or fertility enhancing drugs, devices, products, or services required to be covered under 
sections 5a, 5b, 5c, or 5f.” in its place.     	ENROLLED ORIGINAL 
 
 
 
 
 	2 
(b) A new section 5f is added to read as follows:  
“Sec. 5f. Coverage of fertility treatments. 
“(a)(1) Beginning January 1, 2025, a health insurer offering a large group health benefit 
plan shall provide coverage for the diagnosis and treatment of infertility, including in vitro 
fertilization and standard fertility preservation services, as provided in paragraph (2) of this 
subsection; provided that the treatment would be consistent with a physician’s or surgeon’s 
overall plan of care.  
“(2) The health benefit plan shall cover: 
 “(A) At least 3 complete oocyte retrievals with unlimited embryo transfers 
from those oocyte retrievals or from any oocyte retrieval performed prior to January 1, 2025, in 
accordance with the guidelines of ASRM, using single embryo transfer when recommended and 
medically appropriate; and 
 “(B) The medical costs related to an embryo transfer to be made from an 
enrollee to a third-party; except, that the enrollee’s coverage shall not extend to any medical 
costs of the surrogate or gestational carrier after the embryo transfer procedure.  
“(b)(1) Beginning January 1, 2025, a health insurer offering an individual health benefit 
plan or small group health plan shall provide coverage for the diagnosis and treatment of 
infertility, including in vitro fertilization and standard fertility preservation services, as provided 
in paragraph (2) of this subsection; provided that the treatment would be consistent with a 
physician’s or surgeon’s overall plan of care. 
“(2) The health benefit plan shall cover: 
 “(A) At least 3 complete oocyte retrievals with unlimited embryo transfers 
from those oocyte retrievals or from any oocyte retrieval performed prior to January 1, 2025, in 
accordance with the guidelines of ASRM, using single embryo transfer when recommended and 
medically appropriate; and 
 “(B) The medical costs related to an embryo transfer to be made from an 
enrollee to a third-party; except, that the enrollee’s coverage shall not extend to any medical 
costs of the surrogate or gestational carrier after the embryo transfer procedure. 
“(c)(1) Beginning January 1, 2024, the DC Healthcare Alliance program shall provide 
health insurance coverage for the diagnosis of infertility and any medically necessary ovulation 
enhancing drugs and medical services related to prescribing and monitoring the use of such 
drugs, which shall include at least 3 cycles of ovulation-enhancing medication treatment over an 
enrollee’s lifetime. 
                        “(2) By January 1, 2024, the Department of Health Care Finance shall 
submit an amendment to the Medicaid state plan to the Centers for Medicare & Medicaid 
Services to authorize coverage through Medicaid for the diagnosis of infertility and any 
medically necessary ovulation enhancing drugs and medical services related to prescribing and 
monitoring the use of such drugs, which shall include at least 3 cycles of ovulation-enhancing 
medication treatment over an enrollee’s lifetime.    	ENROLLED ORIGINAL 
 
 
 
 
 	3 
“(d) Within 180 days of the effective date of this section, the Department of Health Care 
Finance shall submit a report to the Council after consulting with the Centers for Medicare & 
Medicaid Services on whether in vitro fertilization and standard fertility preservation services are 
medically reasonable and necessary procedures under federal law, possible methods for covering 
in-vitro fertilization and standard fertility preservation services as a Medicaid covered benefit for 
both fee-for-service and managed care organizations, including any potentially applicable waiver 
authorities, and the amount of money that would need to be allocated to federal and local funds 
for such coverage.  
“(e) Coverage for the treatment of infertility shall be provided without discrimination on 
the basis of age, ancestry, disability, domestic partner status, gender, gender expression, gender 
identity, genetic information, marital status, national origin, race, religion, sex, or sexual 
orientation.  
“(f) A health insurer shall not impose: 
“(1) Deductibles, copayments, coinsurance, benefit maximums, waiting  
periods or any other limitations on coverage for the diagnosis and treatment of infertility,  
including the prescription of fertility medications, different from those imposed upon benefits for 
services not related to infertility; 
 “(2) Pre-existing condition exclusions or pre-existing condition waiting periods 
on coverage for the diagnosis and treatment of infertility or use any prior diagnosis of or prior 
treatment for infertility as a basis for excluding, limiting, or otherwise restricting the availability 
of coverage for required benefits; or 
 “(3) Limitations on coverage based solely on arbitrary factors, including number 
of attempts, dollar amounts, or age, or provide different benefits to, or impose different 
requirements upon, a class protected under the Human Rights Act of 1977, effective December 
13, 1977 (D.C. Law 2-38; D.C. Official Code § 2-1401.01 et seq.), than that provided to, or 
required of, other patients. 
“(g) Nothing in this section shall be construed to interfere with the clinical judgment of a 
physician or surgeon. 
“(h) The health insurer shall notify all policyholders and all prospective group 
policyholders with whom they are negotiating of the availability of coverage provided under this 
section. 
“(i) For the purposes of this section, the term:  
  “(1) “ASRM” means the American Society for Reproductive Medicine. 
 “(2) “Infertility” means a disease, condition, or status characterized by: 
“(A) The failure to establish a pregnancy or to carry a pregnancy to live  
birth after regular, unprotected sexual intercourse in accordance with the guidelines of ASRM; 
“(B) A person’s inability to reproduce without medical intervention either 
as a single individual or with their partner; or 
 “(C) A licensed physician’s findings based on a patient’s medical, sexual, 
and reproductive history, age, physical findings, or diagnostic testing.    	ENROLLED ORIGINAL 
 
 
 
 
 	4 
“(3) “Treatment for infertility” means procedures consistent with established  
medical practices in the treatment of infertility by licensed physicians and surgeons, including 
diagnosis, diagnostic tests, medication, surgery, or gamete intrafallopian transfer.  
“(4) “Standard fertility preservation services” means procedures that are 
consistent with established medical practices or professional guidelines published by ASRM or 
the American Society of Clinical Oncology for a person who has a medical condition or is 
expected to undergo medication therapy, surgery, radiation, chemotherapy, or other medical 
treatment that is recognized by medical professionals to cause a risk of impairment to fertility.   
“(j) The Mayor, pursuant to Title I of the District of Columbia Administrative Procedure 
Act, approved October 21, 1968 (82 Stat. 1204; D.C. Official Code § 2-501 et seq.), shall issue 
rules to implement the provisions of this section.”. 
 
Sec. 3. Applicability. 
 (a) Amendatory section 5f(b) in section 2(b) shall apply upon the date of inclusion of its 
fiscal effect in an approved budget and financial plan. 
(b) The Chief Financial Officer shall certify the date of the inclusion of the fiscal effect in 
an approved budget and financial plan and provide notice to the Budget Director of the Council 
of the certification.  
(c)(1) The Budget Director shall cause the notice of the certification to be published in 
the District of Columbia Register. 
 (2) The date of publication of the notice of the certification shall not affect the 
applicability of this act. 
 
Sec. 4. Fiscal impact statement. 
The Council adopts the fiscal impact statement in the committee report as the fiscal 
impact statement required by section 4a of the General Legislative Procedures Act of 1975, 
approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a). 
 
Sec. 5. Effective date. 
This act shall take effect following approval by the Mayor (or in the event of veto by the 
Mayor, action by the Council to override the veto), a 30-day period of congressional review as 
provided in section 602(c)(1) of the District of Columbia Home Rule Act, approved December  
 
 
 
 
 
 
 
    	ENROLLED ORIGINAL 
 
 
 
 
 	5 
24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(1)), and publication in the District of 
Columbia Register.  
 
 
 
 
______________________________ 
Chairman 
Council of the District of Columbia 
 
 
 
 
 
_________________________________ 
Mayor 
District of Columbia